Acasti Pharma Inc. is a Canadian-based biopharmaceutical company dedicated in the research, development and commercialization of innovative proprietary active pharmaceutical ingredients (API) for the management of cardiometabolic disorders, from prevention to treatment, bridging the treatment gap in lipid management. Acasti produces first-in-class and best-in-class anti-dyslipidemic prescription drugs (“CaPre®”) and medical foods (“Onemia™”) customized to enter the $30 billion dyslipidemia market.
Read more...

Onemia™ is Acasti’s first product to be commercialized in the healthcare practitioner market.

As a medical food, Onemia™ is only administered under the supervision of a physician and is intended for the specific dietary management of illnesses associated with omega-3 phospholipid deficiency related to cardiometabolic disorders.

Read more...

CaPre® is Acasti’s lead prescription drug candidate developed to address the prevention and treatment of cardiometabolic disorders including hypertriglyceridemia, a condition which is characterized by abnormally high levels of triglycerides.

Read more...